New drug and biologics applications deluged the US Food and Drug Administration up through the last days of 2019, including seven potential novel agents in areas from oncology to urology, psychiatry, and blood disorders:
MorphoSys AG announced the completion of the rolling BLA for tafasitamab (MOR208) on 30 December, setting the Fc-enhanced anti-CD19...







